Clinical trials: Dapagliflozin
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using…
- Trial name
- ACHIEVE-2 (NCT06192108)
- Testing
- Orforglipron, Dapagliflozin
- Where
- 74 sites in United States, China and 4 more
- Volunteers
- 962 people
- Sponsor
- Eli Lilly and Company
Immunoglobulin A Nephropathy
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
- Trial name
- PROTECT (NCT03762850)
- Testing
- sparsentan, irbesartan, Dapagliflozin
- Where
- 162 sites in United States, Australia and 16 more
- Volunteers
- 406 people
- Sponsor
- Travere Therapeutics, Inc.
Liver Cirrhosis
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and…
- Trial name
- ZEAL (NCT05516498)
- Testing
- Part A: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin
- Where
- 50 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria.
- Trial name
- MIRO-CKD (NCT06350123)
- Where
- 92 sites in United States, Austria and 13 more
- Volunteers
- 324 people
- Sponsor
- AstraZeneca
Acute Heart Failure, Heart Failure
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital…
- Trial name
- NCT04363697
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 2,401 people
- Sponsor
- The TIMI Study Group
Kidney Transplant Recipients, Post-transplant Diabetes Mellitus
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
This study will be a randomized, double-blind, placebo-controlled clinical trial comparing the SGLT2 inhibitor dapagliflozin to placebo in 52 kidney transplant recipients (KTR) with or without pre-existing type 2 diabetes (T2D)…
- Conditions
- Kidney Transplant Recipients, Post-transplant Diabetes Mellitus, Type 2 Diabetes
- Trial name
- INFINITI2019 (NCT04965935)
- Testing
- Dapagliflozin 10 MG Oral Tablet
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- University Health Network, Toronto
Diabetes Mellitus, Type 2, Endothelial Dysfunction
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes.
- Trial name
- SFRNDM2 (NCT05139914)
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Boston University
Lewy Body Dementia, Parkinson Disease
Anti-Diabetic Medications to Fight PD and LBD
The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
- Trial name
- NCT06263673
- Testing
- Sitagliptin, Dapagliflozin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Liver Cirrhosis
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as…
- Trial name
- ZEAL UNLOCK (NCT06269484)
- Testing
- Zibotentan + dapagliflozin
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 73 people
- Sponsor
- AstraZeneca
Cystinuria
The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
Cystinuria is an inherited autosomal recessive disorder of the kidney that is the result of an inability to reabsorb cystine from the urine.
- Trial name
- NCT04818034
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
PreDiabetes, Obesity, Morbid
Effectiveness of Dapagliflozin for Weight Loss
Mexico has one of the highest prevalence of obesity, reported on 32.4 percent of people over 20 years old, with a prevalence of obesity class III of 1.8 percent on males and 4.1 percent on females.
- Conditions
- PreDiabetes, Obesity, Morbid, Diabetes Mellitus, Type 2
- Trial name
- NCT03968224
- Testing
- Dapagliflozin/Metformin, Metformin
- Where
- Mexico
- Volunteers
- 160 people
- Sponsor
- Centro Medico Nacional Siglo XXI IMSS
Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
The purpose of this study is to examine the effect of the chronic treatment of type 2 diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin signaling/action and (2) oral glucose tolerance…
- Trial name
- DAPA MITO (NCT01439854)
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
SLE, Lupus Nephritis
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
This study aims to assess sodium glucose linked transoprter inhibitors(SGT2i) role in regression of ongoing kidney and cardiac diseases among lupus nephritis patient either diabetic or non-diabetic under different…
- Conditions
- SLE, Lupus Nephritis, SGLT2 Inhibitors
- Trial name
- NCT05748925
- Testing
- dapagliflozin
- Where
- Egypt
- Volunteers
- 84 people
- Sponsor
- Mansoura University
Acute Myocardial Infarction, Heart Failure
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF)…
- Trial name
- DAPA-MI (NCT04564742)
- Testing
- Dapagliflozin
- Where
- 103 sites in Sweden, United Kingdom
- Volunteers
- 4,017 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency
This proposed study will test whether measurement of breath acetone (BrAce) can be used for the purpose of identifying ketosis (elevated ketones) in persons with type 1 diabetes (T1D).
- Trial name
- NCT05541484
- Testing
- SGLT2 inhibitor, Biosense Breath Ketone Analyzer
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Covid19
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
- Trial name
- ACTIV-4A (NCT04505774)
- Testing
- theraputic heparin, prophylactic heparin, P2Y12
- Where
- 101 sites in United States, Brazil and 2 more
- Volunteers
- 3,591 people
- Sponsor
- Matthew Neal MD
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
- Trial name
- NCT04492722
- Testing
- AZD5718, Dapagliflozin 10 mg
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation
This is a multicenter trial to evaluate the impact of treatment with dapagliflozin versus placebo following catheter ablation of atrial fibrillation (AF) on the burden of AF during 6-12 months of follow-up.
- Trial name
- DAPA-AF (NCT04792190)
- Testing
- dapagliflozin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Rochester
Heart Failure, Chronic Kidney Disease
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of…
- Trial name
- MIRACLE (NCT04595370)
- Testing
- AZD9977, Dapagliflozin
- Where
- 156 sites in United States, Belgium and 20 more
- Volunteers
- 153 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients
A prospective, multicenter, phase -IV study to assess the safety of fixed dose combination of dapagliflozin and saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients.
- Trial name
- NCT04445714
- Testing
- dapagliflozin and saxagliptin
- Where
- 9 sites in India
- Volunteers
- 196 people
- Sponsor
- AstraZeneca